Editas Medicine Inc (EDIT)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Yellow, and only just: on the latest evidence none of the hard substance findings that trigger a red light here are present. No filing carries a going concern warning; on May 5, 2026 Editas expressly stated that its funds would last at least twelve months. Equity was almost gone at $4.4 million on March 31, 2026 — but positive, and the May 26, 2026 offering lifted it to a pro forma $121.4 million. Against roughly $241 million of pro forma cash and $23.1 million of operating cash burn in the latest quarter, that reaches well beyond four quarters; there is no callable bank loan, no interest or repayment date that could topple the company, and no listing deadline. What is open is precisely the question everything rests on: since its founding in 2013 not one dollar of product revenue has been booked, $1.65 billion has been consumed, the best in-house program was discontinued on December 11, 2024, and the only recurring cash stream — the Vertex license fees — has been sold to DRI up to 100 percent and now repays debt instead of becoming income. On top of that, the decisive Cas9 patents do not belong to Editas but are in-licensed from Broad and Harvard. What remains is a single preclinical molecule whose first human data Editas itself expects by the end of 2026. A company whose outcome hangs on one readout carries no substance risk in the sense of our traffic light, but no proven quality either — hence yellow. If that readout slips or disappoints, this rating belongs back on the bench. The decision is yours.
symbol.quality_note
Editas was one of the first names in gene editing — and today it is a company without a medicine of its own. Its quarterly report (10-Q) for the period ended March 31, 2026 says it plainly: never any product revenue — and an accumulated deficit of $1.65 billion. What shows up as revenue is license income, mostly for the Cas9 technology behind Vertex's approved CASGEVY. And even those fees have largely belonged to a royalty investor since October 2024. Editas buried its lead program at the end of 2024 and let go 65 percent of its staff; by March 2026 equity was down to $4.4 million, and in May the company raised fresh money by issuing 55.6 million new shares. Not investment advice — just the question of what a pioneer is worth when it helped invent the tool but not the treatment.
Read the analysis
Stock Watch
This analysis is as of July 29, 2026. Stock Watch will tell you what's changed at EDIT since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.60 $ — 36% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralNegativ-Befund, geprüft am 29.07.2026 gegen die sechs jüngsten SEC-Berichte von Editas Medicine (Geschäftsberichte 10-K für 2025, eingereicht 09.03.2026, und für 2024, eingereicht 05.03.2025, sowie die Quartalsberichte 10-Q zum 31.03.2026, 30.09.2025, 30.06.2025 und 31.03.2025): In keinem der vier Quartalsberichte kommt „artificial intelligence“, „machine learning“, „AI“, „generative“, „neural network“ oder „large language model“ überhaupt vor. In den beiden Geschäftsberichten gibt es genau eine Fundstelle, und sie steht in Item 1A unter dem Cybersicherheits-Risiko: Vertrauliche Daten könnten abfließen, weil Beschäftigte, Lieferanten oder Partner generative KI-Werkzeuge oder öffentliche KI-Plattformen benutzen. Das ist eine unveränderte Standardformulierung zum Datenschutz — der Satz steht 2024 und 2025 nahezu wortgleich da — und kein konkreter Bezug zum eigenen Geschäftsmodell; nach der Vorrang-Regel also kein Beleg für „bedroht“. Umgekehrt belegt kein Filing einen eigenen KI-Einsatz: Editas beschreibt seine Plattform durchgängig molekularbiologisch (CRISPR-Nukleasen Cas9 und AsCas12a, Lipid-Nanopartikel-Zustellung, funktionelle Hochregulierung des LDL-Rezeptors), und beschrieb die Off-Target-Bewertung im Geschäftsbericht für 2024 als Kombination aus In-silico-, biochemischen und zellulären Methoden — Rechenverfahren, aber keine als KI ausgewiesene Technologie. Der Umsatz besteht ausschließlich aus Lizenz- und Kollaborationserlösen (40,5 Mio. US-Dollar 2025), nicht aus KI-Produkten. Damit weder „verkauft“ noch „nutzt“ noch „bedroht“: dokumentierter Negativ-Befund, Kategorie neutral.
View the full file — quotes, sources, reviewed filings
„Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees’, vendors’ or partners’ use of generative artificial intelligence (“AI”) technologies or public AI platforms."
Darüber hinaus könnten sensible Daten abfließen, offengelegt oder preisgegeben werden, weil unsere Beschäftigten, Lieferanten oder Partner generative Werkzeuge künstlicher Intelligenz („KI“) oder öffentliche KI-Plattformen nutzen — oder im Zusammenhang mit einer solchen Nutzung.
„Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees’, vendors’ or partners’ use of generative AI technologies."
Darüber hinaus könnten sensible Daten abfließen, offengelegt oder preisgegeben werden, weil unsere Beschäftigten, Lieferanten oder Partner generative KI-Technologien nutzen — oder im Zusammenhang mit einer solchen Nutzung.
Filings Reviewed: 10-Q 2026-05-05 · 10-K 2026-03-09 · 10-Q 2025-11-10 · 10-Q 2025-08-12 · 10-Q 2025-05-12 · 10-K 2025-03-05
Rated on July 29, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 130.8% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 15
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.99 | -1.18 – -0.61 | 15 | 44.8% | 7 |
| 12/31/2027 | -0.96 | -1.15 – -0.46 | 15 | 3.8% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.30 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -0.82 | -46.40 | 1 | -82.20 | -13,178.80 | -57 | -61 |
| 2024: Q3 | -0.75 | -36.40 | 0 | -98.90 | -101,870.50 | -53 | -56 |
| 2024: Q4 | -0.55 | -139.10 | 31 | -49.00 | -148.30 | -51 | -51 |
| 2025: Q1 | -0.92 | -21.10 | 5 | 310.40 | -1,633.50 | -48 | -48 |
| 2025: Q2 | -0.32 | 61.00 | 4 | 597.50 | -1,487.80 | -50 | -50 |
| 2025: Q3 | -0.28 | 62.70 | 8 | 12,265.60 | -333.00 | -31 | -31 |
| 2025: Q4 | -0.06 | 89.10 | 25 | -19.20 | -22.70 | -36 | -36 |
| 2026: Q1 | -0.26 | 71.70 | 3 | -39.20 | -882.40 | -23 | -23 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 6 | -97 | -97 | -3.02 | -50 | 135 | 229 |
| 2017 | 14 | -120 | -120 | -2.98 | -9 | 208 | 373 |
| 2018 | 32 | -114 | -110 | -2.33 | -46 | 236 | 420 |
| 2019 | 21 | -141 | -134 | -2.68 | -41 | 262 | 509 |
| 2020 | 91 | -135 | -109 | -1.87 | -180 | 394 | 573 |
| 2021 | 26 | -193 | -185 | -2.74 | -164 | 554 | 677 |
| 2022 | 20 | -226 | -204 | -2.98 | -177 | 361 | 514 |
| 2023 | 78 | -169 | -153 | -2.02 | -132 | 349 | 499 |
| 2024 | 32 | -251 | -237 | -2.88 | -210 | 134 | 342 |
| 2025 | 41 | -99 | -160 | -1.80 | -165 | 27 | 187 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
By its own statement in the quarterly report (10-Q) for the period ended March 31, 2026, Editas has never generated any product revenue; the annual report (10-K) for 2025 places every program at the preclinical or research stage. The most advanced program, reni-cel, was discontinued on December 11, 2024 — moving the company back from clinical to preclinical status.
The $40.5 million of 2025 revenue consists of collaboration and license income; the $78.1 million peak in 2023 was essentially the $50.0 million Vertex upfront payment. The recurring Vertex fees were sold to DRI Healthcare in October 2024 (up to 100 percent, $57.0 million upfront): they still run through revenue — $10.0 million of annual license fee in fiscal 2025 — but the cash repays the $54.7 million liability (March 31, 2026).
The cost program is complete and working: research and development at $90.0 million (2025) after $199.2 million (2024), administration at $49.9 million after $72.0 million, and a quarterly loss of $25.0 million (Q1 2026) after $76.1 million (Q1 2025). The restructuring line stood at zero in the first quarter of 2026 — the $60.7 million rebuild of 2025 is paid for.
Equity fell from $134.3 million (December 31, 2024) to $27.3 million (December 31, 2025) and $4.4 million (March 31, 2026) against $144.9 million of liabilities. The May 26, 2026 offering brought roughly $117.0 million net but cost more than 56 percent additional shares (97,906,282 to 153,461,838). Company runway estimate: the second half of 2028.
The patents are solid enough that Vertex pays annual fees of $5.0 million to $40.0 million through 2034 and BMS has built 14 programs on them. For EDIT-401 the company reported on May 14, 2026 a mean LDL cholesterol reduction of 90 percent or greater in non-human primates, durable through roughly six months. Human evidence, however, is entirely absent.
Editas Medicine is the pioneer trap in pure form: a co-founder of the CRISPR era whose patents are good enough that Vertex and Bristol Myers Squibb pay for them — yet which, after $1.65 billion of accumulated deficit, has never earned a dollar of product revenue. Its own best program was discontinued on December 11, 2024, 65 percent of the workforce was let go, and the recurring license stream was sold to a royalty investor. Equity was down to $4.4 million on March 31, 2026; the May 26, 2026 offering brought roughly $117.0 million and more than 56 percent additional shares. What remains is a well-funded, extremely concentrated bet on a single preclinical molecule. Not investment advice.
- Editas Medicine reached our research list through the filing calendar of the U.S. securities regulator, the SEC: the current report (8-K) of May 26, 2026 announcing a sale of 55,555,556 shares against roughly 97.9 million then outstanding. We additionally reviewed the annual report (10-K) for 2025, the quarterly report (10-Q) for the period ended March 31, 2026 and every SEC filing through July 29, 2026.
- Every figure carries its own reporting date. The shortest-lived are equity ($4.4 million at March 31, 2026), cash ($123.6 million at March 31, 2026) and share count (153,461,838 after May 27, 2026) — all of which move with each quarterly report and each further capital measure.
- The market value of roughly $402 million is the calculation 153,461,838 shares times a $2.62 closing price as of the July 28, 2026 data cut-off, and it moves with every trading day. The cross-check is the last price Editas itself recorded in an SEC document (prospectus supplement of May 26, 2026, price of May 22, 2026: $2.76, or roughly $424 million) — the gap of a good five percent confirms the order of magnitude. Do not confuse the parties: CASGEVY belongs to Vertex Pharmaceuticals, not to Editas, which holds only a license position in it.
About the Company
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Employees | 87 |
|---|---|
| Headquarters | Cambridge, MA |
| Address | 11 Hurley Street, 02141 Cambridge, United States |
| Phone | 617 401 9000 |
| Website | editasmedicine.com |
| IPO Date | 3. Feb 2016 |
| ISIN | US28106W1036 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gilmore O'Neill M.D. | President, CEO & Director | 1964 |
| Amy Parison | Senior VP & CFO | 1986 |
| Linda C. Burkly Ph.D. | Executive VP & Chief Scientific Officer | 1957 |
| Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member | – |
| George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member | 1954 |
| Gregory Whitehead | Executive VP and Chief Technical & Quality Officer | – |
| Damien Grierson J.D. | Senior VP, General Counsel & Corporate Secretary | – |
| Tom Love | Vice President of People | – |
| Frank Panaccio | Senior VP & Chief Business Officer | – |
| Brieana Buckley | Senior Vice President of Development and Program Leadership | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 28. Jul 2026 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 4,928 | 2.67 | 13,158 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.